Multiplatform Biomarker Discovery for Bladder Cancer Recurrence DiagnosisReportar como inadecuado

Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Disease Markers - Volume 2016 2016, Article ID 4591910, 9 pages -

Research Article

AXO Science SAS, 34 rue du Mail, 69004 Lyon, France

AIT Austrian Institute of Technology GmbH, Konrad-Lorenz-Straße 24, 3430 Tulln, Austria

Department of Oncology, Faculty of Health and Medical Sciences, University of Surrey, Leggett Building, Surrey GU2 7WG, UK

Université de Lyon, Université Lyon 1, CNRS, INSA, CPE-Lyon, ICBMS, UMR 5246, No. 43, boulevard du 11 Novembre 1918, 69622 Villeurbanne Cedex, France

Received 17 May 2016; Accepted 27 July 2016

Academic Editor: Roland Seiler

Copyright © 2016 Marine De Paoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. Nonmuscle invasive bladder cancer BCa has a high recurrence rate requiring lifelong surveillance. Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of recurrent bladder cancer. However, no single marker can achieve the required accuracy. The purpose of this study was to select a multiparameter panel, comprising urinary biomarkers and clinical parameters, for BCa recurrence diagnosis. Experimental Design. Candidate biomarkers were measured in urine samples of BCa patients with recurrence and BCa patients without recurrence. A multiplatform strategy was used for marker quantification comprising a multiplexed microarray and an automated platform for ELISA analysis. A multivariate statistical analysis combined the results from both platforms with the collected clinical data. Results. The best performing combination of biomarkers and clinical parameters achieved an AUC value of 0.91, showing better performance than individual parameters. This panel comprises six biomarkers cadherin-1, IL-8, ErbB2, IL-6, EN2, and VEGF-A and three clinical parameters number of past recurrences, number of BCG therapies, and stage at time of diagnosis. Conclusions. The multiparameter panel could be a useful noninvasive tool for BCa surveillance and potentially impact the clinical management of this disease. Validation of results in an independent cohort is warranted.

Autor: Marine De Paoli, Selma Gogalic, Ursula Sauer, Claudia Preininger, Hardev Pandha, Guy Simpson, Andras Horvath, and Christoph



Documentos relacionados